CliffBio
small molecule

IRINOTECAN HYDROCHLORIDE

IRINOTECAN HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyShilpa Medicare →See this company's full patent-cliff portfolio

Drug detail

Brand nameIRINOTECAN HYDROCHLORIDE
Active ingredientIRINOTECAN HYDROCHLORIDE
Strength40MG/2ML (20MG/ML)
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalDecember 2018
Marketing statusRX

More from Shilpa Medicare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

IRINOTECAN HYDROCHLORIDE patent cliff — loss of exclusivity — | CliffBio